Can Inhaled Pirfenidone Transform Progressive Pulmonary Fibrosis Treatment?

Can MIST Redefine Treatment for Progressive Pulmonary Fibrosis?

The MIST study represents a significant advancement in the quest for effective treatments for Progressive Pulmonary Fibrosis (PPF), a condition characterized by worsening fibrotic changes, increased symptoms, and physiological decline despite standard therapy. With approximately 180,000 patients worldwide suffering from PPF—representing 30-40% of patients with interstitial lung disease (ILD)—there remains a critical need for therapeutic options beyond nintedanib, currently the only FDA-approved treatment. Oral pirfenidone, while effective for idiopathic pulmonary fibrosis (IPF), presents significant challenges in PPF treatment due to dose-limiting adverse events, with studies showing that more than 80% of patients discontinue the medication within three years of initiation. This high discontinuation rate underscores the urgent need for alternative delivery methods that maintain efficacy while reducing systemic exposure and associated side effects.

AP01, an inhaled formulation of pirfenidone delivered via the eFlow Nebuliser System, was specifically developed to address the limitations of oral administration. The inhalation route offers a compelling advantage: higher peak lung concentration of the active ingredient with significantly lower systemic exposure compared to the standard oral dose of 801 mg three times daily. Previous clinical studies have demonstrated that AP01 is well-tolerated, with substantially reduced incidence of the common adverse events typically associated with oral pirfenidone. Moreover, preliminary data from two trials involving IPF patients showed promising results, with those receiving AP01 experiencing less decline in forced vital capacity (FVC) percent predicted at 24 weeks compared to historical placebo groups, and near-stable lung function at 48 weeks. These encouraging findings provide a strong rationale for investigating AP01's potential in the broader PPF population.

How Is the MIST Study Designed to Answer Unmet Needs?

The MIST study is designed as a Phase 2b randomized, double-blind, placebo-controlled trial evaluating the safety, efficacy, and pharmacokinetics of multiple doses of AP01 compared with placebo over 52 weeks in patients with PPF. The study will enroll approximately 300 eligible patients across 150 sites in 14 countries, with participants randomized in a 2:1:2 ratio to receive AP01 100 mg twice daily, AP01 50 mg twice daily, or placebo. Importantly, the study allows for the inclusion of patients on background, stable dose nintedanib therapy (capped at 30% of total enrollment) to reflect real-world treatment scenarios, while oral pirfenidone use is not permitted during the study period. The primary endpoint is the change from baseline in FVC at week 52, with secondary endpoints including changes in quality of life measured by the Living with Pulmonary Fibrosis (LPF) questionnaire, time to disease progression, and changes in fibrosis scores via quantitative high-resolution CT (HRCT).

Patient eligibility criteria have been carefully established to ensure appropriate representation of the PPF population. Male and female patients aged 18 years or older must demonstrate progression of ILD within the 24 months prior to screening, as evidenced by at least one of the following: a relative decline in FVC of at least 10% of predicted value; a relative decline in FVC of 5-10% of predicted value accompanied by worsening respiratory symptoms or increased fibrosis on HRCT; or worsening respiratory symptoms with increased fibrosis on HRCT. At screening, patients must have an FVC greater than 45% of predicted value, a forced expiratory volume in 1 second (FEV1)/FVC ratio of at least 0.7 or meeting age-adjusted lower limit of normal values, and a diffusing capacity of the lung for carbon monoxide (DLCO) of at least 30% of predicted value. Patients with fibrosing lung disease on HRCT, defined as reticular abnormality with traction bronchiectasis (with or without honeycombing) and disease extent greater than 10%, will be classified as having either a usual interstitial pneumonia (UIP)-like fibrotic pattern or other fibrotic patterns based on central review.

The study design incorporates a screening period of up to 4 weeks, during which patient eligibility is assessed, electronic diary compliance is established, and training on the eFlow device is provided. Patients also receive at least one week of open-label nebulized saline to establish a baseline for cough. Following randomization, patients will complete in-clinic assessments at baseline and at weeks 2, 4, 8, 12, 18, 26, 38, 48, and 52, with a follow-up telephone call at week 54. This comprehensive assessment schedule allows for thorough monitoring of treatment effects and safety parameters throughout the study period. Upon completion of the 52-week treatment phase, patients will have the option to continue receiving AP01 by enrolling in an optional open-label extension, providing valuable long-term safety and efficacy data.

What Safety Measures and Analyses Support AP01’s Evaluation?

Safety monitoring is a critical component of the MIST study, with particular attention to adverse events commonly associated with antifibrotic therapies. An independent Data Safety Monitoring Board will conduct periodic reviews of safety data to provide unbiased assessment and recommendations. The study will carefully monitor for abnormal liver biochemistry, changes in vital signs, physical examination findings, body weight, laboratory evaluations, and ECG parameters. Given the inhalation route of administration, special attention will be paid to cough and symptoms of bronchospasm, with protocols in place for management with short-acting beta agonists if necessary. This comprehensive safety monitoring approach aims to identify and address potential concerns promptly while maintaining patient participation in the study whenever possible.

The statistical analysis plan for MIST employs a Treatment Policy estimand to evaluate the effect of intention to treat on patients with PPF with AP01, regardless of adherence to the planned course of treatment. The primary endpoint will be analyzed using a mixed model for repeated measures, with change from baseline in FVC as the dependent variable and treatment, visit, visit by treatment interaction, background use of oral nintedanib, HRCT pattern, need for oxygen, baseline DLCO, age, gender, and baseline FVC as explanatory variables. Time-to-event endpoints, such as time to disease progression, will be analyzed using Cox proportional hazards models. The sample size calculation assumes a mean difference in the primary endpoint between each AP01 group and placebo of 100 mL at week 52, with an SD of 225 mL and a study discontinuation rate of 10%. Under these assumptions, the nominal power to detect a difference from placebo is 90% for the 100 mg twice daily group and 75% for the 50 mg twice daily group.

Could Exploratory Endpoints and Timing Influence Clinical Practice?

The MIST study will also investigate several exploratory endpoints that provide a more comprehensive understanding of AP01's impact on PPF. These include the annual rate of FVC decline over 52 weeks, time to adjudicated death, total number of respiratory deaths, time to first acute PPF exacerbation, and time to first respiratory hospitalization. A PPF exacerbation is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new, widespread alveolar abnormality that cannot be fully explained by cardiac failure or fluid overload. Additionally, changes in DLCO will be measured at screening, baseline, week 26, and week 52 using the single-breath technique according to American Thoracic Society/European Respiratory Society guidelines. Patient-reported outcomes, including cough severity (assessed using an 11-point Likert scale) and quality of life measures (LPF and Leicester Cough Questionnaire), will provide valuable insights into the symptomatic benefits of treatment.

The MIST study's timing is particularly significant given the recent formal definition of PPF in 2022 by international consensus and the growing recognition of the need for well-tolerated therapies for this condition. The study design directly addresses criteria provided by regulatory authorities and expert consortia, incorporating endpoints that reflect not only objective functional assessments but also patients' lived experiences. Could this approach to endpoint selection, combining traditional functional measures with patient-reported outcomes, serve as a model for future clinical trials in interstitial lung diseases? How might the results of the MIST study influence treatment algorithms for PPF, particularly in patients who cannot tolerate or do not respond adequately to nintedanib? These questions highlight the potential broader impact of the study beyond its primary efficacy objectives.

Is Inhaled Delivery the Future of Antifibrotic Therapy?

The innovative approach of delivering pirfenidone directly to the lungs via inhalation represents a promising strategy to overcome the limitations of oral administration while maintaining or potentially enhancing therapeutic efficacy. If successful, AP01 could significantly alter the treatment landscape for PPF, offering patients an option that may reduce respiratory symptoms, decrease the frequency of exacerbations and hospitalizations, and potentially slow disease progression with fewer systemic side effects. What regulatory challenges might arise in implementing this therapy if proven effective, particularly regarding patient selection and positioning relative to existing treatments? How might the availability of an inhaled antifibrotic change clinical practice patterns and patient adherence to therapy in this challenging disease? The answers to these questions await the results of the MIST study, which began in June 2024 with estimated completion in 2026.

Pharmacokinetic assessment is another important component of the MIST study, with blood samples collected for plasma analysis of pirfenidone and its metabolites (5-carboxy pirfenidone and 5-hydroxy pirfenidone) using validated liquid chromatography with tandem mass spectrometry methods. All patients will have blood samples collected at randomization and week 4, with samples taken prior to dosing and 10 minutes after completing administration. Additionally, a subset of up to 50 patients at select sites will undergo more extensive PK sampling at predose, 10 minutes, 30 minutes, 2 hours, 4 hours, and 6 hours post-dose at randomization and week 4. This comprehensive PK assessment will provide valuable insights into the systemic exposure of inhaled pirfenidone compared to historical data for oral administration.

How Do Concomitant Therapies and Quality Controls Enhance Trial Integrity?

The MIST study protocol carefully addresses concomitant medication use to ensure patient safety while reflecting real-world treatment scenarios. Patients receiving standard of care with nintedanib must have been on treatment for at least 6 months prior to screening, with or without dose adjustments during that period. Conversely, patients who have discontinued nintedanib must have been off the medication for a minimum of 12 weeks before screening. The protocol also provides flexibility in managing disease progression during the study; if progression is noted in patients not taking nintedanib, investigators may initiate nintedanib treatment while continuing study drug administration per protocol. Similarly, specific requirements are in place for patients on immunomodulatory therapies, including mycophenolate mofetil, tocilizumab, methotrexate, azathioprine, oral corticosteroids, and rituximab, with defined treatment durations required before screening and after discontinuation.

The study incorporates rigorous quality control measures to ensure data integrity and patient safety. All aspects of the trial will be conducted in accordance with Good Clinical Practice (GCP) guidelines, including the International Conference on Harmonisation (ICH) Guideline for GCP, U.S. Code of Federal Regulations dealing with clinical studies, and the Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Written informed consent, reviewed and approved by institutional review boards or independent ethics committees, will be obtained from all participants. Source documents, including hospital records, procedure reports, and data collection forms, will be used to enter data on case report forms, with processes in place to identify and explain any discrepancies. The sponsor is responsible for implementing and maintaining quality control and quality assurance systems with written Standard Operating Procedures to ensure compliance with all applicable regulations.

Patient confidentiality is maintained through careful handling of identifiable data. On all study-specific documents other than signed consent forms, subjects will be referred to by randomly assigned identification codes. Access to the key linking these codes to identifiable data will be restricted to authorized study site personnel with a need to know such information, and the key will be stored securely by the study site. Access to directly identifying personal information will be limited to the study doctor/collaborators, relevant health authorities, institutional review boards or ethics committees, the sponsor, and authorized personnel, with all parties complying with applicable laws to ensure protection of participant data.

Will MIST’s Comprehensive Assessment Shape Future PPF Management?

The MIST study's comprehensive assessment of AP01 in PPF addresses a significant unmet medical need in a patient population with limited treatment options. The rationale for investigating inhaled pirfenidone is compelling, given the established efficacy of oral pirfenidone in IPF and the mechanistic similarities between IPF and PPF. By delivering pirfenidone directly to the lungs, AP01 has the potential to achieve higher local concentrations while minimizing systemic exposure and associated adverse events. This approach could be particularly beneficial for patients who cannot tolerate oral antifibrotic therapies due to gastrointestinal side effects, liver toxicity, or skin reactions.

The clinical implications of the MIST study extend beyond the primary efficacy endpoint. By incorporating a range of secondary and exploratory endpoints, including patient-reported outcomes and measures of disease progression, the study will provide a comprehensive assessment of AP01's impact on PPF. This multifaceted approach aligns with recent recommendations from regulatory authorities and expert consortia emphasizing the importance of capturing how patients feel, function, and survive in clinical trials for interstitial lung diseases. The inclusion of quality of life measures, such as the LPF questionnaire and Leicester Cough Questionnaire, recognizes the significant symptom burden experienced by patients with PPF and the potential impact of treatment on daily functioning and well-being.

The decision to allow concomitant nintedanib use in a subset of patients reflects the evolving treatment landscape for PPF and acknowledges that combination therapy may be necessary for optimal disease management in some patients. This approach also enhances the generalizability of the study findings to real-world clinical practice, where patients may be receiving multiple treatments for PPF and associated conditions. The careful monitoring of safety parameters, including potential interactions between nintedanib and AP01, will provide valuable information for clinicians considering combination therapy in the future.

The MIST study's design incorporates several innovative features that address challenges specific to clinical trials in PPF. The use of centralized HRCT review to classify patients as having UIP-like or other fibrotic patterns ensures consistency in radiographic assessment and allows for stratification based on this important prognostic factor. The inclusion of a saline nebulization period during screening helps establish a baseline for cough and identifies patients who may experience bronchospasm with inhalation therapy. The comprehensive PK assessment in a subset of patients will provide valuable data on the systemic exposure of inhaled pirfenidone and potential correlations with efficacy and safety outcomes.

Summary

The MIST study is a Phase 2b randomized, double-blind, placebo-controlled trial evaluating AP01, an inhaled formulation of pirfenidone, in approximately 300 patients with Progressive Pulmonary Fibrosis (PPF) across 150 sites in 14 countries. PPF affects approximately 180,000 patients worldwide, representing 30-40% of those with interstitial lung disease, yet treatment options remain limited. While oral pirfenidone is effective for idiopathic pulmonary fibrosis, more than 80% of patients discontinue it within three years due to dose-limiting adverse events. AP01, delivered via the eFlow Nebuliser System, aims to achieve higher lung concentrations with lower systemic exposure, potentially reducing side effects while maintaining efficacy. The study, which began in June 2024 with estimated completion in 2026, randomizes patients in a 2:1:2 ratio to receive AP01 100 mg twice daily, AP01 50 mg twice daily, or placebo over 52 weeks. The primary endpoint is change in forced vital capacity at week 52, with secondary endpoints including quality of life measures, time to disease progression, and changes in fibrosis scores on high-resolution CT. The trial allows concomitant nintedanib use in up to 30% of participants to reflect real-world treatment scenarios. Eligible patients must demonstrate ILD progression within 24 months prior to screening through declining lung function, worsening symptoms, or increased fibrosis. The study incorporates comprehensive safety monitoring by an independent Data Safety Monitoring Board, extensive pharmacokinetic assessment, and multiple exploratory endpoints including exacerbation rates and patient-reported outcomes. If successful, AP01 could significantly alter the PPF treatment landscape by offering a well-tolerated alternative that addresses the limitations of current oral antifibrotic therapies while potentially improving adherence and clinical outcomes.